Teva Pharmaceuticals
Generic and Specialty Pharmaceuticals
Startup Public Health Tech & Life Sciences Est. 1901
Total Raised
$508M
Public
Last Round
$150M
4 rounds
Investors
4
4 public
Team
6
500+ employees
Confidence
93/100
News
632
articles
Patents
1
About
Teva is a global pharmaceutical company that develops, produces, and markets generic drugs, specialty pharmaceuticals, and active pharmaceutical ingredients. Headquartered in Israel, Teva has a product portfolio of more than 3,600 medicines and produces approximately 120 billion tablets and capsules a year at 70 manufacturing facilities. Teva is ranked among the leading pharmaceutical companies in the world and is active in 60 countries, with approximately 43,000 employees worldwide.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesLife SciencesCosmeticsPharmaceuticalsBiotechnology
Business Model
B2CB2B
Tags
respiratorywomen-healthneurologyoncologygeneric-drugsbiological-therapypharmaceuticalspatientsbiopharmaceuticalnanotechnologychronic-patientsdrug-deliverydoctorsmedical-cannabis
Funding & Events
Sep 2015
M&A Undisclosed
Oct 2016
M&A Undisclosed
Oct 2015
M&A $2.3B
May 2011
M&A $6.8B
Mar 2015
M&A $3.5B
Jun 2014
M&A $825M
Jun 2013
M&A $165M
Jul 2008
M&A $7.46B
Jan 2014
M&A $144M
Jan 1982
Exit Undisclosed
Jan 1951
Exit Undisclosed
Feb 2018
PIPE $358M
Berkshire Hathaway, Fidelity Ventures, The Capital Group Companies
Aug 2016
M&A $40B
Aug 1999
M&A $220M
Apr 2024
PIPE $150M
Abingworth (Lead)
News (632)
Oct 31, 2025 · finance.yahoo.com
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
Oct 31, 2025 · uk.finance.yahoo.com
growth-negative
Net zero tax ‘will drive up NHS medicine prices’
Oct 30, 2025 · finance.yahoo.com
growth-positive
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation: Is There Untapped Value After Recent Uptrend?
Oct 29, 2025 · finance.yahoo.com
growth-positive
Trump Administration Eases Approval Process for Biosimilar Drugs
Oct 24, 2025 · finance.yahoo.com
growth-positive
Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe
Partners
Oct 23, 2025 · finance.yahoo.com
growth-positive
Deckers Brands Reports Second Quarter Fiscal Year 2026 Financial Results
Oct 22, 2025 · finance.yahoo.com
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Product StageInvestment
Oct 21, 2025 · finance.yahoo.com
growth-negative
UBS Maintains Bullish Outlook on Deckers Outdoor Corporation (DECK) as Analysts Monitor HOKA’s U.S. Growth Recovery
Oct 21, 2025 · finance.yahoo.com
growth-positive
Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed
FDA approved/pending approval
Oct 21, 2025 · finance.yahoo.com
growth-positive
JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)
Oct 21, 2025 · www.businesswire.com
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Oct 21, 2025 · finance.yahoo.com
growth-positive
Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy
Oct 21, 2025 · finance.yahoo.com
growth-positive
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Oct 21, 2025 · finance.yahoo.com
growth-positive
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Oct 21, 2025 · finance.yahoo.com
growth-positive
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
Oct 21, 2025 · finance.yahoo.com
growth-positive
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy
Oct 20, 2025 · finance.yahoo.com
growth-positive
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Partners
Oct 17, 2025 · finance.yahoo.com
growth-positive
What Recent Earnings Reveal About Teva’s Valuation in 2025
Oct 17, 2025 · finance.yahoo.com
growth-positive
Teva Pharmaceutical Receives FDA Approval to Expand UZEDY Indication for Maintenance Treatment of Bipolar I Disorder
FDA approved/pending approval
Oct 16, 2025 · finance.yahoo.com
growth-positive
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
+ 612 more articles
Details
Product Stage
Released
Employees
500+
Exact Count
29991
District
Center District,Jerusalem District
Founded
1901
Registrar
520013954
Crunchbase
teva-pharmaceutical-industries
Locations
Basel Street 5, Petah Tiqwa, Israel
Kiryat HaMada Street 20, Jerusalem, Israel
1090 Horsham Road, North Wales, PA, USA
Swensweg 5, Haarlem, Netherlands
Laarstraat 16, Antwerp, Belgium
Aston Lane North, Runcorn, UK
Debrecen, Pallagi t 13, Hungary
Links
Website
LinkedIn
Twitter
Facebook
Careers
Admin
Last Update
Nov 1, 2025
Verified by
Sharon Shapira
Missing
markets, not claimed
Team (6)
Richard Francis
President & CEO
David M. Stark
Executive Vice President, Chief Legal Officer
Richard Daniell
EVP - Head of Europe Commercial
Eric Drap
EVP Teva Global Operations
Dr. Hafrun Fridriksdottir
EVP, President of Global Generics R&D
Mark Sabag
Group Executive Vice President, Human Resources
Internal
Created by
Lior Karol (liorkarol@gmail.com)
Created
2014-12-16T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Public on TASE on Jan, 1951<br>Public on NYSE on Jan, 1982<br>